Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. (Q38180195)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

meta-analysis

0 references

title

Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

inflammatory bowel diseases

5 March 2020

main subject

0 references

0 references

0 references

1 reference

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

C J M Williams

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

L Peyrin-Biroulet

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

20 January 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

447-458

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease

5 March 2020

cites work

1 reference

Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease

21 January 2018

1 reference

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

Systematic review: Infliximab therapy in ulcerative colitis.

21 January 2018

1 reference

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis

21 January 2018

1 reference

Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials

21 January 2018

1 reference

Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease

21 January 2018

1 reference

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study

21 January 2018

1 reference

Use of azathioprine and the risk of cancer in inflammatory bowel disease

21 January 2018

1 reference

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

21 January 2018

1 reference

Meta-analysis in clinical trials

21 January 2018

1 reference

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

21 January 2018

1 reference

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

21 January 2018

1 reference

Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study

21 January 2018

1 reference

Infliximab for the treatment of fistulas in patients with Crohn's disease

21 January 2018

1 reference

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

21 January 2018

1 reference

Certolizumab pegol for active Crohn's disease: a placebo-controlled, randomized trial

21 January 2018

1 reference

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

21 January 2018

1 reference

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease.

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.

21 January 2018

1 reference

Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

21 January 2018

1 reference

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

21 January 2018

1 reference

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

21 January 2018

1 reference

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses

21 January 2018

1 reference

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data

21 January 2018

1 reference

The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events

21 January 2018

1 reference

Do inflammatory bowel disease therapies cause cancer?

21 January 2018

1 reference

Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease

21 January 2018

1 reference

Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry

21 January 2018

1 reference

Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III).

21 January 2018

1 reference

Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease

21 January 2018

1 reference

Infliximab prevents Crohn's disease recurrence after ileal resection

21 January 2018

1 reference

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12624

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24444171%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference